StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Cogent Biosciences's profit margin for the twelve months ending Dec 31, 2020 was -950.4%. For fiscal 2020 it was -950.4%, against -141.5% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2020Dec 31, 2020-950.4%−808.9
FY2019Dec 31, 2019-141.5%+213.3
FY2018Dec 31, 2018-354.8%−49.8
FY2017Dec 31, 2017-304.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2020Sep 30, 2020-16020.2%−14851.3
Q2 FY2020Jun 30, 2020-1400.2%−1065.1
Q1 FY2020Mar 31, 2020-86.7%+296.3
Q4 FY2019Dec 31, 201915.0%+241.2
Q3 FY2019Sep 30, 2019-1168.9%−671.2
Q2 FY2019Jun 30, 2019-335.1%+206.5
Q1 FY2019Mar 31, 2019-382.9%−79.6
Q4 FY2018Dec 31, 2018-226.2%+88.9
Q3 FY2018Sep 30, 2018-497.7%−197.4
Q2 FY2018Jun 30, 2018-541.6%−259.6
Q1 FY2018Mar 31, 2018-303.4%+21.7
Q4 FY2017Dec 31, 2017-315.1%–
Q3 FY2017Sep 30, 2017-300.3%–
Q2 FY2017Jun 30, 2017-282.0%–
Q1 FY2017Mar 31, 2017-325.1%–

More Cogent Biosciences figures

See a number that looks wrong?